News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Continue Reading Previous Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNext Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors Related Stories News Typhoon special arrangements for Hong Kong Book Fair, Hong Kong Sports and Leisure Expo and World of Snacks News The List of Gold IRA Companies for 2025 Released by Affiliate Credo News Solodev Achieves Latest AWS Government Competency, Powering Citizen Experiences with AI and Cloud Innovation News International Land Alliance Unveils New Revenue Model Featuring 100 Rental Homes in Cabo Oasis News Virturo Broker Launches Enhanced AI-Powered Trading Suite at London Investor Summit News Legend Power Systems Applies for Amendment to Terms of Warrants